15-Mar-2019 | Zion Market Research
Zion Market Research has published a new report titled “Anticoagulants Market by Drug Class (NOACs, Heparin & LMWH, Vitamin K Antagonist, and Others), by Route of Administration (Injectable Anticoagulant and Oral Anticoagulant), and by Application (Stroke, Atrial Fibrillation, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT), and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025”. According to the report, the global anticoagulants market was valued at approximately USD 26.1 billion in 2018 and is expected to generate around USD 43.6 billion by 2025, at a CAGR of around 7.7% between 2019 and 2025.
Anticoagulants reduce or prevent blood coagulation and delay clotting time. Anticoagulants are prescribed to people who are at a higher risk of developing blood clots. Anticoagulants are prescribed to manage for thrombotic disorders. Oral anticoagulants (OACs) are used by many persons in the form of tablets or pills. Doctors also prescribe anticoagulants to people who have lately undergone surgery.
Browse the full “Anticoagulants Market by Drug Class (NOACs, Heparin & LMWH, Vitamin K Antagonist, and Others), by Route of Administration (Injectable Anticoagulant and Oral Anticoagulant), and by Application (Stroke, Atrial Fibrillation, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT), and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025” Report at https://www.zionmarketresearch.com/report/anticoagulants-market
The growing incidences of cardiovascular disorders, chronic diseases, and venous thromboembolism (VTE), increasing acceptance of novel oral anticoagulants (NOACs), growing awareness regarding the use of NOACs, escalating aging population, dearth of precise substitutes for anticoagulant drugs, advantageous government policies, and rising number of obese people will act as major driving factors of the global anticoagulants market. Increasing investments made by leading market players for developing novel products and offer solutions for high unmet patient needs will create new growth opportunities for the market players in the anticoagulants market. Nevertheless, the high cost of NOACs, the existence of alternative drugs, stringent government regulations, side-effect risks, and complications related to the use of oral anticoagulants may restrict the global anticoagulants market.
The global anticoagulants market is segmented based on drug class, route of administration, and application. By drug class, the anticoagulants market is segmented into NOACs, heparin and LMWH, vitamin K antagonist, and others. NOACs are expected to dominate the market in the future, due to the increasing product awareness. The NOACs is sub-segmented into bevyxxa, eliquis, lixiana and savaysa, pradaxa, and xarelto. The route of administration segment is divided into injectable anticoagulant and oral anticoagulant. The oral anticoagulant segment is expected to dominate the market in the future, owing to the growing availability of cost-effective warfarin. The application segment is segmented into stroke, atrial fibrillation, pulmonary embolism (PE), deep vein thrombosis (DVT), and others. The atrial fibrillation segment is expected to dominate the market, due to a huge target population. Additionally, the deep vein thrombosis (DVT) segment is expected to show the highest CAGR owing to increasing DVT incidences.
By region, North America will lead the global anticoagulants market over the forecast time period, owing to the presence of state-of-the-art healthcare setup, high demand for innovative therapeutics, huge target population, the existence of trained healthcare professionals, and rising incidences of cardiovascular disorders. Europe will be the second largest market for anticoagulants in the years ahead, due to the escalating aging population, rising occurrences of chronic diseases, advantageous government policies, and the rising number of obese people. The Asia Pacific will propagate at a speedy rate over the forecast time period, owing to the huge population, growing number of people suffering from chronic disorders, such as cancer, diabetes, and cardiovascular diseases, promising government policies, and growing investments made by pharmaceutical companies for research and development.
Some players of the global anticoagulants market are Bayer AG, Aspen Holdings, Boehringer Ingelheim GmbH, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, GlaxoSmithKline, Pfizer, Inc., Sanofi S.A., Johnson & Johnson, and Portola Pharmaceuticals, Inc., among others.
This report segments the global anticoagulants market as follows:
Global Anticoagulants Market: By Drug Class
Global Anticoagulants Market: By Route of Administration
Global Anticoagulants Market: By Application
Global Anticoagulants Market: By Region
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651